Penumbra develops innovative medical devices for removing blood clots and treating vascular conditions including ischemic stroke, pulmonary embolism, and acute limb ischemia using its proprietary computer-assisted vacuum thrombectomy (CAVT) technology. The company's product portfolio spans thrombectomy, embolization, vascular access, and neurosurgical markets, with offerings designed to treat clot-based and vascular diseases from head to toe with speed and safety. Penumbra generates revenue through direct sales organizations in the United States, Europe, Canada, Australia, and Singapore, as well as through distributors and licensing arrangements in select international markets, primarily selling to hospitals that bill third-party payors such as Medicare, Medicaid, and private insurers.